Selected research
Industry Growth & Trends
Global Kidney Cancer Targeted Therapy Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Kidney Cancer Targeted Therapy market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Kidney Cancer Targeted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Kidney Cancer Targeted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Kidney Cancer Targeted Therapy is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Kidney Cancer Targeted Therapy market include Aveo Pharmaceuticals, Exelixis, Wyeth, Amgen, Bayer, Pfizer, Roche, Merck and Novartis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Kidney Cancer Targeted Therapy market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Kidney Cancer Targeted Therapy market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Kidney Cancer Targeted Therapy market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Kidney Cancer Targeted Therapy.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Kidney Cancer Targeted Therapy market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Kidney Cancer Targeted Therapy Market by Company
Aveo Pharmaceuticals
Exelixis
Wyeth
Amgen
Bayer
Pfizer
Roche
Merck
Novartis
Eisai
Kidney Cancer Targeted Therapy Segment by Type
Tyrosine Kinase Inhibitors
Anti-VEGF Monoclonal Antibody
mTOR Inhibitors
EGFR Inhibitors
Kidney Cancer Targeted Therapy Segment by Application
Renal Cell Cancer
Renal Pelvis Cancer
Others
Kidney Cancer Targeted Therapy Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Kidney Cancer Targeted Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Kidney Cancer Targeted Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Kidney Cancer Targeted Therapy.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Kidney Cancer Targeted Therapy companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Tyrosine Kinase Inhibitors
- Anti-VEGF Monoclonal Antibody
- mTOR Inhibitors
- EGFR Inhibitors
Applications
- Renal Cell Cancer
- Renal Pelvis Cancer
- Others
Companies covered
- Aveo Pharmaceuticals
- Exelixis
- Wyeth
- Amgen
- Bayer
- Pfizer
- Roche
- Merck
- Novartis
- Eisai
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Kidney Cancer Targeted Therapy Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Kidney Cancer Targeted Therapy Market Size by Region (2021-2032)
- 1.4.1 Global Kidney Cancer Targeted Therapy Market Size by Region (2021-2026)
- 1.4.2 Global Kidney Cancer Targeted Therapy Market Size by Region (2027-2032)
- 1.5 Key Regions Kidney Cancer Targeted Therapy Market Size (2021-2032)
- 1.5.1 North America Kidney Cancer Targeted Therapy Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Kidney Cancer Targeted Therapy Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Kidney Cancer Targeted Therapy Market Size Growth Rate (2021-2032)
- 1.5.4 South America Kidney Cancer Targeted Therapy Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Kidney Cancer Targeted Therapy Market Size Growth Rate (2021-2032)
2 Kidney Cancer Targeted Therapy Market by Type
- 2.1 Type Introduction
- 2.1.1 Tyrosine Kinase Inhibitors
- 2.1.2 Anti-VEGF Monoclonal Antibody
- 2.1.3 mTOR Inhibitors
- 2.1.4 EGFR Inhibitors
- 2.2 Global Kidney Cancer Targeted Therapy Market Size by Type
- 2.2.1 Global Kidney Cancer Targeted Therapy Market Size Overview by Type (2021-2032)
- 2.2.2 Global Kidney Cancer Targeted Therapy Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Kidney Cancer Targeted Therapy Market Size Forecasted by Type (2027-2032)
- 2.3 Global Kidney Cancer Targeted Therapy Market Size by Regions
- 2.3.1 North America Kidney Cancer Targeted Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Kidney Cancer Targeted Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Kidney Cancer Targeted Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Kidney Cancer Targeted Therapy Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Kidney Cancer Targeted Therapy Market Size Breakdown by Type (2021-2026)
3 Kidney Cancer Targeted Therapy Market by Application
- 3.1 Type Introduction
- 3.1.1 Renal Cell Cancer
- 3.1.2 Renal Pelvis Cancer
- 3.1.3 Others
- 3.2 Global Kidney Cancer Targeted Therapy Market Size by Application
- 3.2.1 Global Kidney Cancer Targeted Therapy Market Size Overview by Application (2021-2032)
- 3.2.2 Global Kidney Cancer Targeted Therapy Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Kidney Cancer Targeted Therapy Market Size Forecasted by Application (2027-2032)
- 3.3 Global Kidney Cancer Targeted Therapy Market Size by Regions
- 3.3.1 North America Kidney Cancer Targeted Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Kidney Cancer Targeted Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Kidney Cancer Targeted Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Kidney Cancer Targeted Therapy Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Kidney Cancer Targeted Therapy Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Kidney Cancer Targeted Therapy Industry Trends
- 4.2 Kidney Cancer Targeted Therapy Industry Drivers
- 4.3 Kidney Cancer Targeted Therapy Industry Opportunities and Challenges
- 4.4 Kidney Cancer Targeted Therapy Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Kidney Cancer Targeted Therapy Revenue (2021-2026)
- 5.2 Global Kidney Cancer Targeted Therapy Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Kidney Cancer Targeted Therapy Key Company Headquarters & Area Served
- 5.4 Global Kidney Cancer Targeted Therapy Company, Product Type & Application
- 5.5 Global Kidney Cancer Targeted Therapy Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Kidney Cancer Targeted Therapy Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Kidney Cancer Targeted Therapy Players Market Share by Revenue in 2025
- 5.6.3 2025 Kidney Cancer Targeted Therapy Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Aveo Pharmaceuticals
- 6.1.1 Aveo Pharmaceuticals Company Information
- 6.1.2 Aveo Pharmaceuticals Business Overview
- 6.1.3 Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Aveo Pharmaceuticals Kidney Cancer Targeted Therapy Product Portfolio
- 6.1.5 Aveo Pharmaceuticals Recent Developments
- 6.2 Exelixis
- 6.2.1 Exelixis Company Information
- 6.2.2 Exelixis Business Overview
- 6.2.3 Exelixis Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Exelixis Kidney Cancer Targeted Therapy Product Portfolio
- 6.2.5 Exelixis Recent Developments
- 6.3 Wyeth
- 6.3.1 Wyeth Company Information
- 6.3.2 Wyeth Business Overview
- 6.3.3 Wyeth Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Wyeth Kidney Cancer Targeted Therapy Product Portfolio
- 6.3.5 Wyeth Recent Developments
- 6.4 Amgen
- 6.4.1 Amgen Company Information
- 6.4.2 Amgen Business Overview
- 6.4.3 Amgen Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Amgen Kidney Cancer Targeted Therapy Product Portfolio
- 6.4.5 Amgen Recent Developments
- 6.5 Bayer
- 6.5.1 Bayer Company Information
- 6.5.2 Bayer Business Overview
- 6.5.3 Bayer Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Bayer Kidney Cancer Targeted Therapy Product Portfolio
- 6.5.5 Bayer Recent Developments
- 6.6 Pfizer
- 6.6.1 Pfizer Company Information
- 6.6.2 Pfizer Business Overview
- 6.6.3 Pfizer Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Pfizer Kidney Cancer Targeted Therapy Product Portfolio
- 6.6.5 Pfizer Recent Developments
- 6.7 Roche
- 6.7.1 Roche Company Information
- 6.7.2 Roche Business Overview
- 6.7.3 Roche Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Roche Kidney Cancer Targeted Therapy Product Portfolio
- 6.7.5 Roche Recent Developments
- 6.8 Merck
- 6.8.1 Merck Company Information
- 6.8.2 Merck Business Overview
- 6.8.3 Merck Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Merck Kidney Cancer Targeted Therapy Product Portfolio
- 6.8.5 Merck Recent Developments
- 6.9 Novartis
- 6.9.1 Novartis Company Information
- 6.9.2 Novartis Business Overview
- 6.9.3 Novartis Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Novartis Kidney Cancer Targeted Therapy Product Portfolio
- 6.9.5 Novartis Recent Developments
- 6.10 Eisai
- 6.10.1 Eisai Company Information
- 6.10.2 Eisai Business Overview
- 6.10.3 Eisai Kidney Cancer Targeted Therapy Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Eisai Kidney Cancer Targeted Therapy Product Portfolio
- 6.10.5 Eisai Recent Developments
7 North America
- 7.1 North America Kidney Cancer Targeted Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Kidney Cancer Targeted Therapy Market Size by Country (2021-2026)
- 7.3 North America Kidney Cancer Targeted Therapy Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Kidney Cancer Targeted Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Kidney Cancer Targeted Therapy Market Size by Country (2021-2026)
- 8.3 Europe Kidney Cancer Targeted Therapy Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Kidney Cancer Targeted Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Kidney Cancer Targeted Therapy Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Kidney Cancer Targeted Therapy Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Kidney Cancer Targeted Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Kidney Cancer Targeted Therapy Market Size by Country (2021-2026)
- 10.3 South America Kidney Cancer Targeted Therapy Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Kidney Cancer Targeted Therapy Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Kidney Cancer Targeted Therapy Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Kidney Cancer Targeted Therapy Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst